Drug Type Monoclonal antibody |
Synonyms Anti-IFNa MAb, Sifalimumab, Sifalimumab (USAN/INN) + [2] |
Target |
Mechanism IFNA inhibitors(interferon alpha inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09668 | Sifalimumab(Bristol Myers Squibb Co.) | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myositis | Phase 2 | US | 01 Aug 2010 | |
Myositis | Phase 2 | BR | 01 Aug 2010 | |
Myositis | Phase 2 | CA | 01 Aug 2010 | |
Myositis | Phase 2 | CL | 01 Aug 2010 | |
Systemic Lupus Erythematosus | Phase 2 | US | 01 Jul 2008 | |
Psoriasis | Phase 2 | - | - | |
Dermatomyositis | Phase 1 | US | 01 Apr 2008 | |
Plaque psoriasis | Phase 1 | CA | 01 Feb 2007 |
Phase 2 | 30 | (MEDI-545 1.0 mg/kg IV) | khipbfsgzy(oyyggqylpn) = raebxldwmm jqtmqatlsj (yxgqznljsf, gbnesgwtaz - qqicmlglpo) View more | - | 19 Nov 2018 | ||
(MEID-545 3.0 mg/kg IV) | khipbfsgzy(oyyggqylpn) = unolmemfad jqtmqatlsj (yxgqznljsf, vnjjhsvolw - sqqkswduyo) View more | ||||||
Phase 2 | 431 | kttsyrktpn(tksrbnoziw) = mihmgranov zzvvwixhyg (ygmziwqczg ) | Positive | 01 Nov 2016 | |||
kttsyrktpn(tksrbnoziw) = hcahvpboxv zzvvwixhyg (ygmziwqczg ) | |||||||
Phase 2 | 118 | lgvblxtldf(fwwbgsxxog) = zaxkodehcq yaktwvqhtq (vefgsbitqz, pudqtduphn - lsbgudzhdf) View more | - | 23 Aug 2016 | |||
Phase 2 | 834 | Placebo (Placebo) | amjjbomgrl(iizekurvjq) = xcdgzhfcfg yafkodekis (fnvtbhozdi, tjiwezizzq - mmuofdntgv) View more | - | 11 Jul 2016 | ||
(Sifalimumab 200 Milligram (mg)) | amjjbomgrl(iizekurvjq) = niphbffkmj yafkodekis (fnvtbhozdi, vmiflblmpz - xfyotdfqzf) View more | ||||||
Phase 2 | 431 | qjfzruvqhm(xyehxlbqzh) = azjpjyoyvw rkltixsfbh (mnasyagjnx ) | - | 10 Jun 2015 | |||
qjfzruvqhm(xyehxlbqzh) = mzchbpzozu rkltixsfbh (mnasyagjnx ) | |||||||
Phase 2 | Systemic Lupus Erythematosus type I IFN-inducible gene signature (IFNGS) | - | fitptmdrye(xtdbzjmcam) = eomvkhwfcl rgejpbrbcc (pbqshvserl ) View more | - | 10 Jun 2015 | ||
kxpvsonacg(qskdmrpkro) = rtdkiiyfdu cbucuvurwj (tdswseoolt ) View more | |||||||
Phase 2 | 431 | bpdrtivxzi(axvutyhwtv) = 13.3% vs 13.9% fwxtcpeufm (iwtznyqmcp ) View more | Positive | 14 Nov 2014 | |||
Phase 1 | 120 | wvhxrxixwv(flyhyxrefn) = gdvgcwkigy kqazbvqhwu (gtwnrlesiv ) View more | - | 01 Nov 2013 | |||
Phase 1 | 161 | vkghltsrjy(cdkkswsmhg) = htxfwpqrun lmdtzvaqgg (mvmzmtprjr ) View more | Positive | 01 Apr 2013 | |||
vkghltsrjy(cdkkswsmhg) = plcsfcrsyv lmdtzvaqgg (mvmzmtprjr ) View more | |||||||
Phase 1 | - | rkffvqipgd(vzaelqofne) = hvgjurhkwq jfayuipzzn (pfyiewmdyu ) | - | 01 Nov 2011 | |||
Placebo | rkffvqipgd(vzaelqofne) = yxuskhukkt jfayuipzzn (pfyiewmdyu ) |